Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.

@article{Bleeker2008EstimationOD,
  title={Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.},
  author={Wim W K Bleeker and Martin Emilio Munk and Wendy J. M. Mackus and Jeroen H.N. van den Brakel and Marielle Pluyter and Martin J. Glennie and Jan G. J. van de Winkel and Paul W H I Parren},
  journal={British journal of haematology},
  year={2008},
  volume={140 3},
  pages={303-12}
}
We evaluated the dose requirements for sustained in vivo activity of ofatumumab, a human anti-CD20 antibody under development for the treatment of B cell-mediated diseases. In a mouse xenograft model, a single dose, resulting in an initial plasma antibody concentration of 5 microg/ml, which was expected to result in full target saturation, effectively inhibited human B-cell tumour development. Tumour growth resumed when plasma concentrations dropped below levels that are expected to result in… CONTINUE READING